Cargando…
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer
Small cell lung cancer (SCLC) is a difficult to treat subtype of lung cancer. One of the hallmarks of SCLC is its almost uniform chemotherapy sensitivity. However, chemotherapy response is typically transient and patients frequently succumb to SCLC within a year following diagnosis. We performed a t...
Autores principales: | Doerr, Fabian, George, Julie, Schmitt, Anna, Beleggia, Filippo, Rehkämper, Tim, Hermann, Sarah, Walter, Vonn, Weber, Jean-Philip, Thomas, Roman K., Wittersheim, Maike, Büttner, Reinhard, Persigehl, Thorsten, Reinhardt, H. Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686113/ https://www.ncbi.nlm.nih.gov/pubmed/29138515 http://dx.doi.org/10.1038/s41598-017-15840-5 |
Ejemplares similares
-
Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017) -
KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm?
por: Wittersheim, Maike, et al.
Publicado: (2017) -
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021) -
Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017) -
Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)